Brexit: Insulin Stockpiles are built up

Recommendation
29/30 April 2025
Hamburg, Germany
Batch Manufacturing Documents: from Preparation to Operational Excellence
Although all parties involved are looking for a positive outcome of the current negotiations, a so called "hard Brexit" - a scenario in which the U.K. leaves the EU without a full agreement - is possible. This will cause problems in many areas. Preparations are being made in order to deal with it.
According the article "UK's biggest insulin manufacturer building up four-month stockpile in case of no-deal Brexit" in the Independent, about 50% of the insulin needed in the U.K to treat diabetic patients is manufactured by the Danish company NovoNordisk. The company now said that they will build up a stockpile until January 2019 to make sure these diabetic patients will get their medications in the event of a no-deal Brexit. The plan is to have a stockpile lasting for four months. Also the French company Sanofi promised to build up an insulin stockpile (for 14 weeks). The U.K. government has asked companies to build up a six-week stockpile of medications against the consequences of hard Brexit.
Related GMP News
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years
09.04.2025Q&A Document on QP Declaration updated
02.04.2025Switzerland: Update of the Technical Interpretation on the PQR